Pan-Nevada Gold (Tier2) (PNV) News

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the...

Form 424B5 - Prospectus [Rule 424(b)(5)]

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology...

Form DEFR14A - Revised definitive proxy soliciting materials